Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
6
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Job creation lowest on record among under-30s
-
9
Industry experts predicts tough choices as NewJeans' ultimatum nears
-
10
NK troops disguised as 'indigenous' people in Far East for combat against Ukraine: report
-
Daewoo E&C Q2 results to be in line with expectations
[THE INVESTOR] South Korean builder Daewoo E&C’s second-quarter earnings will meet market expectations, LIG Investment & Securities said on July 19. The securities firm expected that Daewoo E&C would post 2.73 trillion won (US$2.42 billion) in sales in the April-June period, up 5.8 percent from a year earlier. Its operating profit is likely to fall 5.6 percent to 98.4 billion won. “The Q2 earnings will be on a par with market consensus because of improved revenue from domestic housing and constr
July 19, 2016
-
Samsung Biologics, Sillajen likely to be listed by year-end: analysts
[THE INVESTOR] Samsung Biologics and Sillajen are likely to be listed by the end of this year, according to analysts on July 19. Samsung Biologics is preparing to apply for preliminary assessment by the Korea Exchange by August this year. Once listed, the stock value is expected to reach around 10 trillion won (US$8.77 billion). The company posted a second straight year of loss in 2015, with the amount widening to 203.6 billion won from 119.5 billion won in 2014. Samsung Biologics headqartersAna
July 19, 2016
